Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


The nonhuman animal is a model for human disease

Subclass of:

800 - Multicellular living organisms and unmodified parts thereof and related processes

800008000 - NONHUMAN ANIMAL

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
800010000 Cancer 38
800012000 Alzheimer`s disease 5
20090133135Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases - The present invention discloses a dysregulation of the SLC39A12 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A12 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed.05-21-2009
20130133090TRANSGENIC MAMMALLS MODIFIED IN BRI PROTEIN EXPRESSION - Provided are non-human mammals comprising a knock-in nucleic acid sequence capable of causing an alteration of expression of wild-type Bri2 in the mammal or a knockout of wild-type Bri2. Also provided are the non-human mammals as a model for Alzheimer's disease.05-23-2013
20090217395Promoter Mutations that Increase Amyloid Precursor Protein Expression - The present invention relates to mutations in the amyloid precursor protein (APP) promoter region, whereby the mutations cause a significant increase in APP expression. The increase in APP expression is related to Alzheimer's disease, and the mutations can be used in Alzheimer's disease diagnosis, or in the construction of transgenic animal models for studying Alzheimer's disease.08-27-2009
20120266263METHOD OF TREATING MEMORY DISORDERS AND ENHANCING MEMORY USING IGF-II COMPOUNDS - The present invention provides compositions of insulin-like growth factor II (IGF-II) peptides or nucleic acids for the treatment of memory disorders and to enhance memory in subjects in need thereof.10-18-2012
20120331573DYNACTIN SUBUNIT p62 BIOMARKER FOR NEUROLOGICAL CONDITIONS - Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).12-27-2012
800011000 Immunodeficiency disease 4
20130086705COMPOSITIONS AND METHODS FOR REDUCING AND DETECTING VIRAL INFECTION - The invention provides methods and compositions for screening candidate compounds for activity in altering the level of expression of Schlafen (Slfn) in cells, tissues and animals. The invention also provides methods and compositions for screening candidate compounds for activity in altering the level of virus infection. The invention further provides methods and compositions for screening candidate compounds for altering the level of expression of virus proteins without substantially unfaltering the level of expression of cellular proteins. The invention additionally provides methods and compositions for diagnosing the risk and/or susceptibility to virus infection. The invention also provides transgenic non-human animals, and transgenic cells, comprising a mutant Schlafen (Slfn) gene, such as a knockout mutation. These invention's compositions and methods are useful as models for virus infection, and for screening candidate prophylactic and/or therapeutic anti-viral compounds.04-04-2013
20110113496TRANSGENIC NON-HUMAN ANIMAL AND METHODS FOR STEM CELL ENGRAFTMENT - Transgenic immunodeficient non-human animals according to embodiments of the present invention are described which include in their genome a nucleic acid encoding xenogeneic Stem Cell Factor operably linked to a promoter. Administration of xenogeneic hematopoetic stem cells to the inventive transgenic animals results in engraftment of the xenogeneic hematopoetic stem cells and xenogeneic leukocytes are produced in the animals, without conditioning such as without conditioning by irradiation and without conditioning by a radiomimetic agent.05-12-2011
20100275278ANIMAL MODEL FOR HIV INDUCED DISEASE - HIV does not cause disease in any non-human species. Thus, there is no animal model system to evaluate the efficacy of strategies aimed at preventing, treating or curing disease caused by this virus. The present invention provides compositions and a method for producing an animal model for HIV induced disease. The present invention is an animal adapted to simulate a human-like immune response to HIV, which is accomplished by activation and inactivation of complement of proteins within the animal. Accordingly, the present invention stages certain human proteins within an animal by way of its gut associated lymphoid tissue followed by infection of live HIV.10-28-2010
20110167507Animal Model Having a Chimeric Human Liver and Suceptible to Human Hepatitis C Virus Infection - The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.07-07-2011
Entries
DocumentTitleDate
20130031646MODEL SYSTEM OF ACANTHAMOEBA KERATITIS SYNDROME AND METHOD FOR SELECTING A TREATMENT THEREOF - Methods for generating a feline model for ocular complications arising from amoeba infection are described. The invention further relates to screening methods for therapeutics for the treatment of ocular complications using the feline model referenced to above.01-31-2013
20120266262METHODS AND COMPOSITIONS RELATING TO ZPA POLYPEPTIDES - The present invention provides ZPA polypeptides, antibodies, nucleic acid molecules, antagonists, agonists, potentiators and compositions relating to ZPA polypeptides, and methods of identifying, making and using the same, that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides model systems for the intrinsic apoptotic pathway.10-18-2012
20130031645METHOD FOR HEPATIC DIFFERENTIATION OF DEFINITIVE ENDODERM CELLS - The present invention relates to a method for obtaining a population of hepatic progenitor cells, said method comprising a step of culturing definitive endoderm cells with a culture medium stimulating hepatic specification. In a particular embodiment, such culture medium stimulating hepatic specification comprises a retinoic acid receptor (RAR) agonist, an FGF family growth factor and an inhibitor of the activin signaling pathway.01-31-2013
20090077677MAMMALIAN GRAINYHEAD TRANSCRIPTION FACTORS - The present invention relates generally to diagnostic and therapeutic agents. More particularly, the present invention provides mammalian transcription factors which function in the modulation of expression of genetic sequences. The present invention further provides nucleic acid molecules encoding the transcription factors as well as nucleic acid and/or proteinaceous molecules with which the transcription factors interact. The transcription factors of the present invention or molecules interacting with same may be used inter alia in the generation of a range of diagnostic and therapeutic agents for a range of conditions.03-19-2009
20110197290METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ARTIODACTYLS - Swine animal models comprising a genomic disruption of an endogenous gene chosen from the group consisting of a Low-Density Lipoprotein Receptor gene LDLR, Duchene's Muscular Dystrophy (DMD) gene, and hairless gene (HR). Methods of preparing transfected cells useful for making a transgenic animal comprising exposing a first group of cells to a transfection agent and reseeding the group with additional cells that have not been exposed to the agent. The transgenic animals are useful for medical and scientific animal models of human diseases and conditions, as well as sources for cells, tissues, and biomaterials.08-11-2011
20130086703PERIODONTAL-DISEASE-SPECIFIC PEPTIDE, AND TREATMENT AND DIAGNOSIS OF PERIODONTAL DISEASE USING SAME - The present invention provides an inhibitor of an autoimmune response to a periodontal bacterial enzymatic degradation product of keratin in gingival epithelium in a mammal having a periodontal bacterium in the oral cavity, containing a substance having affinity to the keratin or a degradation product thereof and/or a substance having affinity to an autoantibody to the degradation product, an agent for the prophylaxis and/or treatment of a periodontal disease and/or a complication thereof; a RANKL expression inhibitor containing a substance having affinity to the keratin or a degradation product thereof; and a method of diagnosing a periodontal disease including detecting the keratin or a degradation product thereof and/or an autoantibody thereto.04-04-2013
20130086704PHARMACEUTICAL COMPOSITION UTILIZING PANCREATIC BETA CELL PROLIFERATION FACTOR - Disclosed are a pharmaceutical composition, a screening method, and the like which use UDP-glucose glycoprotein glycosyl transferase 1 (UGGT1) or a gene encoding the same. UGGT1 has an extremely high proliferative activity compared to known pancreatic β-cell proliferation factors; thus, UGGT1 can act as a useful therapeutic agent for diabetes without any modification and is also useful as a target substance for the development of a new therapeutic agent for diabetes.04-04-2013
20130081148NRIP KNOCKOUT MICE AND USES THEREOF - The present invention directs to a transgenic NRIP knockout mouse, the genome of which is manipulated to comprise a disruption of a nuclear receptor interaction protein (NRIP) gene, wherein the NRIP gene is disrupted by deletion of exon 2, the mouse exhibits a phenotype comprising abnormal muscular function. The present invention also directs to a method for making a transgenic NRIP knockout mouse whose genome comprises a homozygous disruption of the NRIP gene, the mouse exhibits abnormal muscular function.03-28-2013
20130042331ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.02-14-2013
20130042330HUMANIZED M-CSF MICE - Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.02-14-2013
20130042332Device and method for inducing brain injury in animal test subjects - An apparatus and method for inflicting brain injury on a laboratory animal that employs a platform for supporting the laboratory animal. The platform defines an opening for positioning the head of the laboratory animal over the opening. A projectile is launched from a projectile launching device orientated below the opening of the platform. The projectile launching device has a means for propelling the projectile directly at and/or through the opening of said platform, thereby inflicting brain injury on the animal via either a pressure wave or concussive impact of the projectile. Without helmet, direct impact of the projectile results in severe traumatic brain injury. Use of helmet protects animals from skull fracture, subdural hematoma, intracerebral hemorrhage and contusion yet produces mild concussion-like pathology.02-14-2013
20120167237ANIMAL MODELS AND THERAPEUTIC MOLECULES - The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.06-28-2012
20130047273Genetically altered animal specimen and related methods - A genetically altered animal specimen is provided by a process comprising: identifying a gene that is desired to be altered, disrupting the gene in a gene carrier to thereby create a new DNA fragment; inserting the new DNA fragment into an embryonic cell, injecting the embryonic cell which exhibits the desired genetic alteration into an embryo, inserting the embryo into a uterus of a carrier whereby the carrier's offspring shall exhibit the desired genetic alteration, and the offspring is the genetically altered animal specimen, in this case the neurocalcin δ gene knockout mouse model.02-21-2013
20120192295COMPOSITION COMPRISING EXTRACELLULAR MEMBRANE VESICLES DERIVED FROM INDOOR AIR, AND USE THEREOF - The present application relates to a composition comprising extracellular membrane vesicles derived from indoor air. In addition, the present application provides a method for diagnosing, preventing and/or treating an inflammatory respiratory disease, lung cancer and the like using the extracellular membrane vesicles. In detail, the present application involves injecting extracellular membrane vesicles present in indoor air into an animal in order to prepare an animal respiratory disease model, and enables the search and/or discovery of drug candidates for preventing or treating respiratory diseases using the animal model. The present application provides a vaccine for preventing and/or treating respiratory diseases, to a method for diagnosing substances causing respiratory diseases, and to a method for inhibiting the activities of extracellular membrane vesicles in indoor air or removing the extracellular membrane vesicles from indoor air so as to prevent the occurrence and exacerbation of respiratory diseases.07-26-2012
20130074199Compositions and Methods for Brown Fat Induction and Activity Using FNDC5 - The invention provides compositions and methods for brown fat induction and activity through modulation of Fndc5 activity and/or expression. Also provided are methods for preventing or treating metabolic disorders in a subject through modulation of Fndc5 activity and/or expression. Further provided are methods for identifying compounds that are capable of modulating Fndc5 activity and/or expression.03-21-2013
20130061339METHOD OF DIAGNOSING TRICHOTILLOMANIA AND SIMILAR DISORDERS IN HUMANS AND RODENTS - The present disclosure provides a method of diagnosing neurological disorders including for example, impulse control disorders, such as barbering and trichotillomania using biomarkers such as reductive capacity of urine and 8-OH-dG concentration. Still other disorders that can be diagnosed based on the measurements of makers for oxidative stress include autism and Parkinson's disease.03-07-2013
20120117671STEATOHEPATITIS-LIVER CANCER MODEL ANIMAL - Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.05-10-2012
20120272345DIAGNOSIS MARKER, DIAGNOSIS METHOD AND THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS, AND ANIMAL MODEL AND CELL MODEL DEVELOPING AMYOTROPHIC LATERAL SCLEROSIS - Provided are a diagnosis marker, a diagnosis method, and a therapeutic agent suitable for diagnosing and treating amyotrophic lateral sclerosis (ALS). Also provided are an animal model and a cell model suitable for developing a therapeutic agent and a treatment method for ALS. The diagnosis method for ALS includes: an isolation step in which a nucleic acid is isolated from a specimen taken from a subject; a detection step in which bases expressed in a human chromosome 10 optineurin (OPTN) gene region are detected from the isolated nucleic acid; and a determination step in which it is determined whether or not the detected bases are mutated.10-25-2012
20080295189Construction of Arterial Occlusive Disease Animal Model11-27-2008
20120278908METHOD FOR THE DIAGNOSIS/PROGNOSIS OF AGE-RELATED MACULAR DEGENERATION - The present invention relates to a method for diagnosing or predicting age related maculopathy or age-related macular degeneration, or a risk of age related maculopathy or age-related macular degeneration, in a subject, said method comprising detecting in a sample obtained from said subject at least one polymorphism in the SCARB1 gene, wherein the presence of said polymorphism is indicative of non age related maculopathy or age-related macular degeneration or of a risk of age related maculopathy or age-related macular degeneration.11-01-2012
20110283371Stem Cell Modified Animal Model for Aging-Related Degenerations, Stem Cell Based Methods and Compositions for Extending Lifespan and Treating SLE-Like Autoimmune Diseases - This invention discloses a stem cell modified animal model useful as a research tool for investigating aging-related degeneration processes and treatments. The animal model is preferably a rodent subcutaneously transplanted with a mesenchymal stem cell capable of generating a functional bone or marrow element. Also provided are a method for extending the lifespan and improving the quality of life of a subject by subcutaneously transplanting a plurality of mesenchymal stem cells to the subject, wherein the mesenchymal stem cells are capable of generating a functional bone or marrow element. Compositions and source of stem cells suitable for use with the methods of this invention, including stem cells from human exfoliated deciduous teeth (SHED), are also disclosed. Further disclosed is a method for identifying progenitor bone marrow mesenchymal stem cells, and a method for treating SLE-like autoimmune diseases by infusion of mesenchymal stem cells.11-17-2011
20110289608ANTISENSE MODULATION OF INTERLEUKINS 17 AND 23 SIGNALING - Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.11-24-2011
20100275277INFECTED NAIL OF ANIMAL INFECTED WITH FUNGUS - The invention can produce an infected nail of an animal and an infected animal model in which the nail plate and nail bed of the nail are sufficiently infected with a superficial fungus which were difficult to be produced in the past, and provides an evaluation method useful for development of a therapeutic agent for intractable infectious diseases such as tinea unguium using the nail and the infected animal model. For producing the infected nail of an animal and the infected animal model infected with a superficial fungus, an immunosuppressive component is administered to an animal in advance to decrease immunocompetence, and then, a superficial fungus is inoculated into the animal, whereby the infected nail of an animal and the infected animal model reflecting clinical manifestation in which the nail plate and nail bed of the nail are sufficiently infected with the superficial fungus can be produced with good reproducibility in a short period of time.10-28-2010
20090138976ANIMAL MODEL FOR HEPATITIS C VIRUS INFECTION - The current document relates to transgenic rodents that have a nucleic acid molecule encoding a hepatocyte mitogen polypeptide.05-28-2009
20120110684Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy - The present invention relates to a method for diagnosing or predicting a non syndromic autosomal recessive optic atrophy, or a risk of a non syndromic autosomal recessive optic atrophy.05-03-2012
20130219530Leishmania Challenge Model - The present invention provides a method for effectively and reproducibly infecting canines with 08-22-2013
20090300777Novel apoptosis inducing factor and method of inducing apoptosis using the same - The purpose of the present invention is to provide a system in which an apoptosis-inducing factor is expressed in an expression promoter-dependent manner, which is not a system wherein a toxin is introduced externally, and a novel protein that can enhance an apoptosis signal used in the system.12-03-2009
20090183268METHODS AND SYSTEMS FOR MEDICAL SEQUENCING ANALYSIS - Disclosed are methods of identifying elements associated with a trait, such as a disease. The methods can comprise, for example, identifying the association of a relevant element (such as a genetic variant) with a relevant component phenotype (such as a disease symptom) of the trait, wherein the association of the relevant element with the relevant component phenotype identifies the relevant element as an element associated with the trait, wherein the relevant component phenotype is a component phenotype having a threshold value of severity, age of onset, specificity to the trait or disease, or a combination, wherein the relevant element is an element having a threshold value of importance of the element to homeostasis relevant to the trait, intensity of the perturbation of the element, duration of the effect of the element, or a combination. The disclosed methods are based on a model of how elements affect complex diseases. The disclosed model is based on the existence of significant genetic and environmental heterogeneity in complex diseases. Thus, the specific combinations of genetic and environmental elements that cause disease vary widely among the affected individuals in a cohort. The disclosed model is an effective, general experimental design and analysis approach for the identification of causal variants in common, complex diseases by medical sequencing. The disclosed model and the disclosed methods based on the model can be used to generate valuable and useful information.07-16-2009
20120144509NOVEL STRAINS OF HELICOBACTER PYLORI AND USES THEREOF - The present invention relates to strains of 06-07-2012
20110173709ECTOPIC, ORTHOTOPIC MODEL FOR REVASCULARIZATION AND TUMOR ASSESSMENT - Improved vascularization and tumor models, comprising a test animal having a dorsal skin window chamber, and an exogenous tissue sample implanted ectopically in the skin within the window chamber, are described, as are methods of using the models.07-14-2011
20100287630MODELS FOR VACCINE ASSESSMENT - The present invention is directed to methods for constructing and using in vivo and in vitro models of aspects of human immunity and, in particular, construction of a human immune system model for the testing of, for example, vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals. The present invention comprises both in vivo and in vitro models of aspects of human immunity that are useful for assessing the interaction of substances with the immune system, and thus can be used to accelerate and improve the accuracy and predictability of, for example, vaccine, drug, biologic, immunotherapy, cosmetic and chemical development. The invention is also useful for the generation of human monoclonal and polyclonal antibodies.11-11-2010
20100005534SASPASE KNOCKOUT ANIMAL - Knockout animals in which a gene encoding a SASPase has been deleted (hereinafter, referred to as SASPase KO animals) are provided. The SASPase KO animals deficient in expression of functional SASPase were produced by deleting a gene encoding a stratified epithelium-specific protease, SASPase, through targeted disruption. The SASPase KO animals showed a significant increase in wrinkles on the sides of the body and so on. The SASPase KO animals find utility as animal models of wrinkles.01-07-2010
20100138943IDENTIFICATION OF GROUP OF HYPERTENSION-SUSCEPTIBILITY GENES - A genetic marker including a SNP which can be used for assessing the risk of developing hypertension, a polynucleotide for assessing the risk of developing hypertension which can be used as a primer or probe for detecting the genetic marker, a method for assessing the risk of developing hypertension using the SNP, a microarray for assessing the risk of developing hypertension which is used for genotyping of the SNP, a kit used in the method for assessing the risk of developing hypertension, and the like.06-03-2010
20120198577Method of Isolating Human Neuroepithelial Precursor Cells from Human Fetal Tissue - A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.08-02-2012
20120198576METHODS FOR MAKING EMBRYONIC CELLS, EMBRYOS, AND ANIMALS SENSITIZED TO STRESS - Embodiments of the invention are based upon the discovery that exposure of cleavage-stage embryos to a stress inducer, e.g. heat shock or chemical, renders the exposed embryos more sensitive to a secondary treatment with a stress inducer, e.g. heat shock or chemical inducer. Accordingly, the present invention is directed to methods for making embryos, embryonic cells arising from them, and animals and plants that are sensitized to stress, e.g. physiologic or chemical stressors. Methods of screening for inducers and inhibitors of stress using, as test model systems, embryonic cells, embryos, animals, and plants that are sensitized to stress are also disclosed.08-02-2012
20090025096P4HAS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE - Human P4HA genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of P4HA are provided.01-22-2009
20110225661METHOD FOR TREATING AND PREVENTING RADIATION DAMAGE USING GENETICALLY MODIFIED MESENCHYMAL STEM CELLS - A method of treating or preventing radiation damage by administering to a patient in need of treatment at least one therapeutically effective amount of a mesenchymal stem cell genetically altered to secrete extracellular superoxide dismutase is provided. Also provided is a therapeutic for treating and/or preventing radiation related or damage by similar agents, the therapeutic contains genetically modified mesenchymal stem cells capable of secreting extracellular superoxide dismutase.09-15-2011
20090013420Psmcs as Modifiers of the Rb Pathway and Methods of Use - Human PSMC genes are identified as modulators of the RB pathway, and thus are therapeutic targets for disorders associated with defective RB function. Methods for identifying modulators of RB, comprising screening for agents that modulate the activity of PSMC are provided.01-08-2009
20090019558PGDS AS MODIFIERS OF THE PTEN PATHWAY AND METHODS OF USE - Human PGD genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of PGD are provided.01-15-2009
20120079612Dry eye animal model - A first embodiment is a dry eyed animal model method by peri or post-menopausal estrogen-treated rats have decreased tear production wherein the menopausal rat may be produced by ovariectomy Chronic estrogen exposure can decrease tear production in rats receiving a nine month course of estrogen versus placebo treatment after ovariectomy. The aged, chronically estrogen-treated female rats can provide a suitable model for the study of KCS and its treatment.03-29-2012
20090217394Diabetes Model Animal - The present invention relates to a diabetes animal model. Specifically, the present invention relates to a transgenic nonhuman animal, into which recombinant DNA comprising a gene encoding a diphtheria toxin receptor and an insulin promoter for regulating expression of the above gene has been introduced.08-27-2009
20100154069PIG MODEL - The present invention relates to a genetically modified pig comprising at least one site for integration of at least one transgene. The invention also pertains to a porcine embryo, blastocyst, foetus, donor cell and/or cell nucleus, derived from said genetically modified pig. In another aspect, the invention relates to any genetically modified porcine blastocyst, wherein the genetically modified genome comprises at least one site for integration of at least one transgene.06-17-2010
20100186101DIAGNOSIS AND TREATMENT OF FERTILITY CONDITIONS USING A SERINE PROTEASE - The invention relates to the use of a serine protease, which is specifically expressed in association with embryo implantation and placentation in pregnant uterus in the evaluation of fertility and monitoring of early pregnancy, placental development and function, fetal development, parturition, and conditions such as pre-eclampsia, intrauterine growth restriction, early abortion, abnormal uterine bleeding, endometriosis, and cancers.07-22-2010
20100263065MATERIALS AND METHODS FOR GENE MEDIATED THERAPY OF PSYCHIATRIC DISORDERS - The invention provides materials and methods for p11-mediated therapy of psychiatric disorders. The invention provides vectors for increasing p11 expression and methods of treating a mammal with one or more symptoms of a psychiatric disorder. The invention also provides methods for improving a mammal's responsiveness to treatment for a psychiatric disorder. The invention further provides model animals for depression and depression therapy.10-14-2010
20100146649Purkinje Cell-Tropic Viral Vector - The present invention relates to a Purkinje cell-tropic viral vector in which a modified L7 promoter and a therapeutic gene are operably linked to a virus-based plasmid vector.06-10-2010
20100235931Novel Neurological Function of mPKCI - Wildtype and mice lacking the gene encoding PKCI/HINT 1 (PKC09-16-2010
20100251394TREATMENT AND PREVENTION OF ISCHEMIC BRAIN INJURY - The invention provides methods of identifying agents for treating and preventing ischemic brain injury.09-30-2010
20090241205METHOD FOR IDENTIFYING CRMP MODULATORS - The present invention refers to a method for identifying a modulator of CRMP suitable for the prevention, alleviation or/and treatment of CRMP-associated diseases.09-24-2009
20110131669GANGLIOSIDE EPITOPES FOR TREATING GUILLAIN-BARRE SYNDROME - Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation.06-02-2011
20130145485METHODS AND COMPOSITIONS FOR ALTERATION OF A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE - Nucleases and methods of using these nucleases for alteration of a CFTR gene and generation of cells and animal models.06-06-2013
20110119775HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF - The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.05-19-2011
20100058488PROTEIN FORMULATIONS COMPRISING S1-5 - The present inventors discovered that knockout mice whose S1-5 gene function is lost develop age-related diseases or symptoms. In such knockout mice, bone mineral content, bone mineral density, and bone strength were found to be decreased, and the number of osteoclasts in bone tissues was found to be increased. Analysis of osteoclast-forming ability using bone marrow cells derived from the knockout mice revealed that osteoclast-forming ability is enhanced and osteoclasts are larger in the knockout mice than in wildtype mice. When purified S1-5 protein was added to this in vitro system, osteoclast-forming ability was inhibited. Furthermore, administration of purified S1-5 protein to osteoporotic model mice showed that this protein has the effect of improving osteoporosis. The above findings demonstrate that S1-5 protein is useful for treating and preventing age-related diseases such as osteoporosis.03-04-2010
20110252487COMPOSITION FOR INDUCING TH2 CELL, THERAPEUTIC COMPOSITION FOR TH2-TYPE DISEASE, AND USE OF SAME - The present invention provides a complex of an antigen and IgE binding to the antigen, a composition including an antigen and IgE binding to the antigen, and a method of using the complex or the composition. With the present invention, it is possible to induce naive T cells to develop into Th2 cells. Moreover, the present invention clarified a working mechanism of a Th2-type immune response, particularly a production mechanism of early IL-4. With use of the present invention, it is possible to provide a technique of treating and preventing Th2-type diseases.10-13-2011
20110099645ANIMAL MODEL FOR CIGARETTE-SMOKE-INDUCED ATHEROSCLEROSIS AND RELATED METHODS - Provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of the effects of environmental stimuli on the development and progression of pathological conditions. The environmental stimuli can include, but are not limited to, exposure to tobacco (e.g., cigarette, etc.) smoke. Exemplary pathological conditions include, but are not limited to, atherosclerosis, other cardiovascular disease (CVD), and the like. Also provided herein are non-human animal models and related methods useful for the identification, characterization, and analysis of pharmaceutical compounds, compositions, and/or formulations that can be used to prevent or treat a given pathological condition brought on by exposure to a given environmental condition.04-28-2011
20110078804Angiogenin and Amyotrophic Lateral Sclerosis - Methods and compositions for treating neurodegenerative disorders are provided. Transgenic animal models of neurodegenerative disorders are provided. Knockout animal models of neurodegenerative disorders are also provided. Mutant angiogenin polypeptides are also provided.03-31-2011
20110258713COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION - The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.10-20-2011
20110067123MAO-B ELEVATION AS AN EARLY PARKINSON'S DISEASE BIOMARKER - This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong prognostic indicator for the disease. Accordingly, in certain embodiments, methods are provided for identifying a mammal at risk for Parkinson's disease. The methods typically involve determining level of expression or activity of monoamine oxidase B (MAO-B) in a sample from the mammal wherein an elevated level of MAO-B expression and/or activity as compared to a control (reference) is an indicator that the mammal has an increased likelihood of developing Parkinson's disease.03-17-2011
20110041193NON-HUMAN MAMMAL MODEL OF EPILEPSY - The present invention provides a genuine epilepsy model animal as an improvement over conventional epilepsy model animals which are socalled seizures model animals mainly causing seizure attacks to be forcibly induced. Also provided is a method that allows for easy identification of the recombinants.02-17-2011
20110030073THERAPEUTIC TARGETS AND MEDICAMENTS INVOLVING P230/GOLGIN-245 - The present invention relates generally to the field of cell biology and in particular the cellular processes surrounding inflammation. Even more particularly, the present invention provides targets for medicaments useful in reducing levels of TNF-alpha, an extracellular pro-inflammatory mediator. The medicaments are therefore useful in modulating inflammatory responses. Model inflammatory disease systems also form part of the present invention.02-03-2011
20090241206METHODS FOR CLONING FERRETS AND TRANSGENIC FERRET MODELS FOR DISEASES - The invention provides a transgenic Mustelidae in which a gene associated with a human disease or condition comprises a targeted genetic modification, and uses thereof. Also provided is a method to cryopreserve Mustelidae embryos or cells, and to enhance the number of live offspring from cryopreserved Mustelidae embryos.09-24-2009
20110055939METHOD FOR INTRODUCING FOREIGN GENE INTO EARLY EMBRYO OF PRIMATE ANIMAL AND METHOD FOR PRODUCING TRANSGENIC PRIMATE ANIMAL COMPRISING SUCH METHOD - An object of the present invention is to provide a method for introducing a gene into an embryo for production of a human disease model primate animal using a non-human primate animal such as a marmoset. The present invention relates to a method for introducing a foreign gene into an early embryo of a non-human primate animal, which comprises placing early embryos of a non-human primate in a 0.2 M to 0.3 M sucrose solution, so as to increase the volume of the perivitelline spaces, and then injecting a viral vector containing a human foreign gene operably linked to a promoter into the perivitelline spaces of the early embryos.03-03-2011
20080250513LACTOBACILLUS N-DEOXYRIBOSYL TRANSFERASES, CORRESPONDING NUCLEOTIDE SEQUENCES AND THEIR USES - The invention concerns novel polypeptides and their fragments, isolated from 10-09-2008
20080250512Restless Legs Syndrome and Periodic Limb Movement Disorder Model Animal - The present invention provides a model animal of Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD). As a result of intraperitoneal administration to a mouse of the plasma constituents in peripheral blood collected from renal failure patients in whom RLS and PLMD were diagnosed, it was found that the mouse remarkably showed behavior pathognomonic in these diseases, and hence can be used as a model mouse of these diseases. The model animal of the present invention can be used for not only the identification of a causative substance of RLS and PLMD, but also the development and evaluation of a diagnostic method and therapy for these diseases.10-09-2008
20110061115Lung rpogenitor cells, assays, and uses thereof - Substantially enriched mammalian lung endothelial and epithelial progenitor cell populations are provided. Methods are provided for the isolation and in vivo differentiation of such lung progenitor cells. The progenitor cells are obtained from lung tissue, including fetal and adult tissues. The cells are useful in transplantation, for experimental evaluation, and as a source of lineage and cell specific products, including mRNA species useful in identifying genes specifically expressed in these cells, and as targets for the discovery of factors or molecules that can affect them.03-10-2011
20120311729Immunomodulatory Methods and Systems for Treatment and/or Prevention of Atherosclerosis - Immunostimulatory methods and systems for treating or preventing atherosclerosis and/or a condition associated thereto in an individual.12-06-2012
20120311728METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS - The present invention relates to the prevention or treatment of atherosclerosis, in particular to a group X sPLA2 polypeptide for use in the treatment of atherosclerosis.12-06-2012
20110088103ALLERGIC DISEASE MODEL ANIMALS - The object of the present invention is to provide a mouse model for allergic diseases such as atopic dermatitis, and a dermatitis mouse model with impaired skin-barrier function. The present inventors found out that a mouse that has been caused to completely lose the function of expressing profilaggrin protein and filaggrin protein by entirely or partially disrupting the endogenous gene encoding filaggrin by a genetic mutation such as deletion or replacement, can be used as a mouse model for allergic diseases or atopic dermatitis wherein the skin-barrier function has been impaired.04-14-2011
20110035818DIAGNOSTIC MARKER AND PLATFORM FOR DRUG DESIGN IN MYOCARDIAL INFARCTION AND HEART FAILURE - Methods for determining the susceptibility of an individual to a heart condition, post myocardial infarction, comprising detecting the presence of an amino acid change in the sequence of the hemopexin domain of MMP-9 (Matrix Metalloproteinase 9), the presence of an amino acid change in said domain being indicative of susceptibility to said heart condition, post myocardial infarction is described, together with methods for drug design.02-10-2011
20090300778Neutral Sphingomyelinase-E and Its Use - The present invention provides a neutral sphingomyelinase-3 (nSMase3), a nucleic acid encoding said nSMase3, a vector containing said nucleic acid, and cells and non-human organisms transformed or transfected with said nucleic acid sequence or vector. The invention furthermore relates to the use of said nSMase3 as pharmaceutical or diagnostic agent. Test systems for candidate active agents for their therapeutic potential in diseases connected with nSMase3 are also provided.12-03-2009
20090300776COMPOSITIONS FOR PREVENTING, REDUCING OR TREATING KERATINOCYTE-MEDIATED INFLAMMATION - The present invention relates to the field of epidermal repair. More particularly, the invention concerns the use of a molecule able to inhibit a heteromeric receptor comprising OSMRβ as a subunit, for the preparation of a composition for inhibiting the expression of inflammatory factors by the keratinocytes. In particular, the invention concerns the use of antagonists and/or expression inhibitors of OSM, IL-17, TNFα, IL-31, IFN-γ, and/or the OSMRβ subunit, for the preparation of cosmetic or dermatologic compositions, especially for treating inflammatory skin diseases.12-03-2009
20110265194THEM5-MODIFIED MODELS OF NON-ALCOHOLIC FATTY LIVER DISEASE - The invention provides a new reproducible genetically-modified mouse model for the study of non-alcoholic fatty liver disease. In particular, the invention concerns the study of non-alcoholic fatty liver disease in an THEM5 knockout mouse model and its use in drug discovery and research.10-27-2011
20100169989Use of Follistatin-Like Related Gene (FLRG) to Increase Muscle Mass - The present relates to use of follistatin-like related gene (FLRG) to increase muscle mass in a subject. As such, methods of ameliorating the severity of a pathologic condition characterized, at least in part, by a decreased amount, development or metabolic activity of muscle are provided. In addition transgenic non-human mammals expressing FLRG and having increased muscle mass as compared to a corresponding mammal having a myostatin-null mutation or a decreased level of myostatin are provided.07-01-2010
20120151612NON-SURGICAL APPROACH TO PREVENT AND CORRECT CRANIOFACIAL MALFORMATIONS DURING DEVELOPMENT - The present invention discloses a novel TGF-β signaling mechanism implicated in craniofacial malformation as well as methods and compositions for treating craniofacial malformation utilizing knowledge of the mechanism. Methods of the invention generally comprises administering an effective amount of a TGF-β inhibitor to a subject in need of the treatment. Also disclosed are methods for treating craniofacial malformation by administering Tgf-β, Tgf-βRIII, p38 MAPK inhibitor or neutralizing antibodies to a subject. Also disclosed is a diagnostic method for diagnosing patients at risk of developing craniofacial malformation by determining the level of Tgf-β2 and ectopic p38 MAPK activation. Compounds useful for treating craniofacial malformation may also be discovered by using animal models of the present invention.06-14-2012
20120073002PREVENTION AND TREATMENT OF BLOOD COAGULATION-RELATED DISASES - Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.03-22-2012
20080216183Model of infantile spasm syndrome - Provided are non-human mammals treated with doxorubicin, lipopolysaccharide (LPS), and p-chlorophenylalanine (PCPA), where the mammal exhibits a symptom characteristic of infantile spasms. Also provided are methods of making a non-human mammal exhibit a symptom of infantile spasms. Additionally, methods are provided for screening a compound for the potential to attenuate a symptom of infantile spasms.09-04-2008
20090038021Novel clock gene and application of the same - It is intended to provide a novel gene encoding a new protein which interacts with BMAL2 protein. Namely, a novel gene comprising any one of the following DNAs (a) to (e): (a) a DNA comprising any one of the base sequences represented by SEQ ID NOS: 1 to 4; (b) a DNA that comprises a base sequence derived from the base sequence of the DNA (a) by deletion, substitution or addition of one to several bases and encodes a protein interacting with BMAL2 protein; (c) a DNA that comprises a base sequence derived from the base sequence of the DNA (a) by deletion, substitution or addition of one to several bases and is hybridizable with the DNA (a) under stringent conditions; (d) a DNA that comprises a base sequence derived from the base sequence of the DNA (a) by deletion, substitution or addition of one to several bases and has a homology of 90% or higher with the DNA (a); and (e) a DNA comprising a base sequence that is complementary to any one of the DNAs (a) to (d).02-05-2009
20120060231METHOD AND KIT FOR EVALUATION OF PREDISPOSITION TO DEVELOPMENT OF OBESITY, ANTI-OBESITY AGENT AND METHOD FOR SCREENING THEREOF, NON-HUMAN ANIMAL, ADIPOSE TISSUE, ADIPOCYTE, METHOD FOR PRODUCTION OF TRANSGENIC MOUSE, ANTIGEN, AND ANTIBODY - It is an object of the present invention to provide a method of evaluating whether or not a subject has a predisposition to obesity or an obesity-related condition or disease, a kit for conducting the method, an anti-obesity drug having an effect of preventing or treating obesity or an obesity-related condition or disease, a method of screening the anti-obesity drug, a non-human animal having a deficiency in the gene associated with obesity, and an adipose tissue or adipocyte of the animal.03-08-2012
20120060230METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS - Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.03-08-2012
20120159658EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF - The present application relates to extracellular vesicles (EVs) derived from gram-positive bacteria. In detail, the present application provides animal models of disease using extracellular vesicles derived from gram-positive bacteria, provides a method for screening an active candidate substance which is capable of preventing or treating diseases through the animal models of disease, provides vaccines for preventing or treating diseases caused by extracellular vesicles derived from gram-positive bacteria, and provides a method for diagnosing the causative factors of diseases caused by gram-positive bacteria using extracellular vesicles.06-21-2012
20120124682DHX36 / RHAU KNOCKOUT MICE AS EXPERIMENTAL MODELS OF MUSCULAR DYSTROPHY - The present invention provides a genetically-modified non-human animal whose somatic and germ cells contain a gene encoding an altered form of an DHX36 gene, the altered DHX36 haviang been targeted to replace a wild-type DHX36 gene into the animal or an ancestor of the animal at an embyonic stage using embryonic stem cells. An ideal use of the genetically-modified non-human animal of the invention is the use as an experimental model for muscular dystrophy, e.g. spinal muscular atrophy, to identify e.g. new treatments for muscular dystrophy and or study its pathogenesis.05-17-2012
20110107442Treatment of Male Sexual Dysfunction - A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.05-05-2011
20120222141ISLET1 (ISL1) AND HEARING LOSS - Described are methods and compositions for increasing islet-1 (Isl1) activity (e.g., biological activity) and or expression (e.g., transcription and/or translation) in a biological cell and or in a subject.08-30-2012
20120216304HUMANIZED ANIMALS VIA TISSUE ENGINEERING AND USES THEREOF - Engineered human tissue constructs are provided that are suitable for use in making humanized animals for use in pharmaceutical development. Humanized animals having the constructs implanted in vivo are provided. Methods of making and using the tissue-engineered constructs and humanized animals are also provided.08-23-2012
20120216303NOVEL THERAPEUTIC USES OF HUMAN FORMYL PEPTIDE RECEPTOR ANTAGONISTS - The invention features a transgenic mouse that expresses human formyl peptide receptor and methods for producing this mouse. The invention also features methods for the measurement of an inflammatory response, particularly that associated with cystic fibrosis. The methods of the invention also feature methods for determining whether a compound inhibits or prevents the recruitment of neutrophils.08-23-2012
20100050278Application of Actin-Binding Protein to Disease Associated With Cell Motility - It is intended to identity a protein involved in a molecular mechanism between Akt and cell motility as well as to elucidate its function and find its application. In the present teachings, for achieving the above object, protein or partial peptide thereof containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID: 2 is utilized in the screening of a compound or a salt thereof that activates or inhibits any of cell motility, cell migration and angiogenesis.02-25-2010
20120180149DOUBLE MUTANT MOUSE AND CELL LINES - A mutant transgenic mouse and cell line derived from the mouse are disclosed. The mutant transgenic mouse was developed from a cross between a mutant mouse which carries mutant genes that express a phenotype similar to human Hermansky-Pudlak Syndrome, and a mouse strain containing a transgene encoding a temperature sensitive protein that is inactive at physiological temperatures. The resulting mutant mouse is characterized by the presence of the HPS mutations as well as the transgene. The mutant mouse and cell lines derived from the lung tissue of the mouse are useful models for lung pathology associated with human HPS, lung fibrosis and inflammation. Methods and assays utilizing the cell lines also are disclosed.07-12-2012
20120180148TRANSGENIC MOUSE MODEL FOR DEVELOPING ENZYME REPLACEMENT THERAPY FOR IDURONATE-2-SULFATASE DEFICIENCY SYNDROME - The present invention relates to a transgenic mouse model for developing enzyme replacement therapy for iduronate-2-sulfatase deficiency syndrome, for example, Hunter syndrome. More specifically, the present invention relates to a transgenic mouse to be used for developing enzyme replacement therapy for iduronate-2-sulfatase, wherein the immune response against injected enzyme, such as, recombinant iduronate-2-sulfatase has been minimized in transgenic mouse model in the course of treating in vivo iduronate-2-sulfatase replacement.07-12-2012
20080301824Parkin interacting polypeptides and methods of use - The invention provides parkin binding polypeptides and encoding nucleic acids. The invention also provides antibodies specific for the parkin binding polypeptides. The invention additionally provides methods of detecting a parkin binding polypeptide and detecting a nucleic acid encoding a parkin binding polypeptide. The invention further provides methods of using a parkin binding polypeptide. In one embodiment, the invention provides a method of identifying a candidate drug for treating Parkinson's disease by contacting a parkin binding polypeptide with one or more compounds and identifying a compound that alters the activity of the parkin binding polypeptide.12-04-2008
20120266260DIAGNOSING AND TREATING IGA NEPHROPATHY - Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.10-18-2012
20120240245Methods and compositions for detecting and treating retinal diseases - The invention discloses multiple genes related to age-related macular degeneration (AMD) and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes. Also provided are nonhuman transgenic animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD. Several preferred embodiments of the therapeutic compositions and animal models are based on target genes MT1-MMP and casein kinase 1 epsilon (CK1ε), phagocytosis-related genes found to be over-expressed in human donor eye samples from patients having both wet and dry forms of AMD.09-20-2012
20120266261NEUROVIRULENT STRAIN OF THE WEST NILE VIRUS AND USES THEREOF - Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and uses thereof.10-18-2012
20110047633Control of Exocrine Pancreatic Function Using Bone Morphogenetic Proteins - Methods are described for controlling exocrine pancreatic function, for reducing the level of amylase in the blood, and for treating pancreatitis in an individual comprising administering to the individual a bone morphogenetic protein (BMP). Methods for identifying candidate molecules for use in treating diabetes are also described.02-24-2011
20110047632Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis - Compositions and methods are provided for prognostic classification of rheumatoid arthritis disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest.02-24-2011
20110271356HCV ENTRY FACTOR, OCCLUDIN - The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV—susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.11-03-2011
20100229251Methods and Compositions for Detecting and Treating End-Stage Cardiomyopathy Using Claudin-5 - The present invention provides a method for diagnosis end-stage cardiomyopathy includes measuring expression of claudin-5 levels in a patient suspected of suffering from end-stage cardiomyopathy as well as a method for treating end-stage cardiomyopathy includes administering an effective amount of a composition effectively upregulates the claudin-5 or inhibits degradation of claudin-509-09-2010
20100229250TREATMENT AND PREVENTION OF ISCHEMIC BRAIN INJURY - The invention provides methods of identifying agents for treating and preventing ischemic brain injury.09-09-2010
20100229249IDENTIFICATION OF GROUP OF HYPERTENSION-SUSCEPTIBILITY GENES - Provided in the present invention is a genetic marker including a SNP which can be used for assessing the risk of developing hypertension, a polynucleotide for assessing the risk of developing hypertension which can be used as a primer or probe for detecting the genetic marker, a method for assessing the risk of developing hypertension using the SNP, a microarray for assessing the risk of developing hypertension which is used for genotyping of the SNP, a kit used in the method for assessing the risk of developing hypertension, and the like.09-09-2010
20130019326Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Metabolic Disorders - The invention provides methods and compositions for selectively promoting anti-metabolic disorder activity over classical PPAR gamma activation through modulation of PPAR gamma phosphorylation (e.g., Ser-273 phosphorylation of murine peroxisome proliferator activated receptor gamma (PPAR gamma) 2 or a corresponding serine residue in a murine PPAR gamma 2 homolog, including a human). Also provided are methods for preventing, treating, or predictiving responsiveness of therapies for metabolic disorders in a subject through selective inhibition of such PPAR gamma phosphorylation. Further provided are methods for identifying compounds that are capable of modulating such PPAR gamma phosphorylation.01-17-2013
20130024957GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., 01-24-2013
20120291147GRAVITATIONAL FLUCTUATION STRESS LOADING METHOD, AIRCRAFT, AIRCRAFT-FLYING METHOD, METHOD FOR PROMOTING SEROTONIN-PRODUCING GENE EXPRESSION, SEROTONIN-PRODUCING METHOD, METHOD FOR STIMULATING CENTRAL NERVOUS SYSTEM, AND EFFICACY-MEASURING METHOD - A gravitational fluctuation stress loading method capable of causing a new acute stress reaction in a subject or a laboratory animal is provided. A gravitational fluctuation stress loading method including at least one first stress-loading step (S11-15-2012
20100199361Role of Proteoglycans in Drug Dependence - The invention provides methods of preventing or treating drug addiction, or ameliorating the craving for an addictive drug, as well as compounds, peptides, and pharmaceutical compositions that may be used to prevent or treat drug addiction or ameliorate the craving for an addictive drug. The invention also provides methods for identifying agents that may be used to prevent or treat drug addiction, or ameliorate the craving for an addictive drug.08-05-2010
20100199362WNT LIGANDS INVOLVED IN BLOOD-BRAIN BARRIER DEVELOPMENT AND USES THEREFOR - Provided are methods of diagnosing and treating vascular disorders of the CNS or disorders of the blood-brain barrier comprising the use of Wnt ligands involved in the canonical Wnt signaling pathway.08-05-2010
20100132058Methods and materials for determining pain sensitivity and predicting and treating related disorders - Methods of treating somatosensory disorders and modulating production of proinflammatory cytokines by administering to a subject an effective amount of a COMT modulator, ADRB2 modulator, ADRB3 modulator or combinations thereof are provided. Methods of predicting effective pharmacological therapies for a subject afflicted with a somatosensory disorder by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided. Methods of determining pain responses or pain perception and predicting susceptibility of a subject to develop related disorders, such as somatosensory disorders and somatization, by determining a genotype of the subject with regard to a gene selected from the group consisting of COMT, ADRB2, ADRB3, and combinations thereof are further provided.05-27-2010
20120255044URATE TRANSPORTER, AS WELL AS METHOD AND KIT FOR EVALUATING URATE TRANSPORT-RELATED DISEASE FACTOR AND INFLAMMATION-RELATED DISEASE FACTOR, AND TEST SAMPLE AND DRUG - A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F208S, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.10-04-2012
20120255043MICRORNA AS A CANCER PROGRESSION PREDICTOR AND ITS USE FOR TREATING CANCER - The present invention is based on the findings that a novel function for miR142-3p in the regulation of Sox2, adenylyl cyclase 9 (AC9), and CD133 expressions, and consequently the overall stemness of recurrent GBM cells as well as CSCs, and that miR142-3p modulated tumor-initiating properties in recurrent GBM. The present invention consequently supports the development of novel miRNA-based strategies for brain tumor treatment.10-04-2012
20080216182Animal Model for the Human Immune System, and Method for Producing the Same - In a method for preparing an animal model for the human immune system in a non-human mammal, human stem cells with hematopoietic potential are transplanted into a non-human mammal. The non-human mammal is conditioned with cell culture supernatant of a culture of human cell lines, cells and/or tissue. The cell culture supernatant is derived from cell lines producing cytokines and other molecular mediators.09-04-2008
20100281550FACTOR INVOLVED IN LATENT INFECTION WITH HERPESVIRUS, AND USE THEREOF - Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder.11-04-2010
20100299768Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease - Isolated double-stranded short interfering nucleic acid molecules inhibiting the expression of endogenous wild-type and exogenous human mutant huntintin genes in cells of a non-human mammal which are expressing both said huntingtin genes, and their application for the treatment of Huntington's disease as well as to study Huntington's disease in rodent models.11-25-2010
20090100534MUSCLE LAMIN A/C INTERACTING PROTEIN, GENE ENCODING SAME, AND USES THEREFOR - Peptide sequences of human and murine muscle lamin A/C interacting protein and nucleotide sequences encoding same and are provided. Uses of the muscle lamin A/C interacting protein are also provided herein.04-16-2009
20110321181DEVICE TO BE PLACED IN BLOOD VESSEL, ANGIOSTENOSIS MODEL USING SAME AND METHOD FOR MAKING MODEL - An indwelling vascular device is constructed such that a vascular stenosis model can be controlled from the partial stenosis to the total occlusion. There is also described a vascular stenosis model of such non-human animal, and a method for making the same. The model can be used for diagnosis or therapy of a disease resulting from the stenosis or total occlusion in a blood vessel or further for the development of therapeutic approaches. The indwelling vascular device includes a device substrate containing a metal and/or metal compound which elutes toxic metal ions at least from a surface thereof and having a structure ensuring a vascular flow immediately after indwelling in a blood vessel, and a polymer coating layer formed on at least a metal and/or metal compound containing surface of the substrate.12-29-2011
20110321180COMPOSITIONS AND METHODS TO GENERATE PILOSEBACEOUS UNITS - The invention provides compositions and methods to generate pilosebaceous units. In one aspect, the invention comprises a biocompatible scaffold and an effective amount of dermal and epidermal precursor cells.12-29-2011
20130191933METHODS OF TREATING PAIN AND MORPHINE TOLERANCE VIA MODULATION OF HEDGEHOG SIGNALLING PATHWAY - Described herein are methods of treating nociception by administering to a subject in need thereof a therapeutic amount of one or more compounds which modulate the Hedgehog signaling pathway.07-25-2013
20130191934TREATMENT OF SYMPTOMS ASSOCIATED WITH MENOPAUSE - A method for treating symptoms associated with a dramatic reduction in reproductive hormone levels is provided, particularly in menopausal women and breast cancer survivors undergoing aromatase inhibitor therapy. The method comprises administered to a subject an inhibitor of orexin activity in an amount sufficient to reduce or decrease onset, progression, severity, frequency, duration or probability of one or more such symptoms. A method of detecting compounds having activity for relieving menopausal symptoms is also provided.07-25-2013
20120030779COMPOSITIONS AND METHODS FOR DETECTING, TREATING, OR PREVENTING REDUCTIVE STRESS - Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compo-sitions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.02-02-2012
20130198875RNA SEQUENCE-SPECIFIC MEDIATORS OF RNA INTERFERENCE - The present invention relates to a 08-01-2013
20120066780HUMANIZED NSG MOUSE, METHOD OF PRODUCING THE SAME AND USE THEREOF - A mouse model in which human fetal thymus and human fetal bone fragments are transplanted into NSG mice, a method of producing the same, and a use thereof.03-15-2012
20120066779HEPATITIS C RECEPTOR PROTEIN CD81 - The present invention relates to the use of CD81 protein and polynucleic acid in the therapy and diagnosis of hepatitis C and pharmaceutical compositions, animal models and diagnostic kits for such purposes.03-15-2012
20130097717COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES - The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as fibroblast cells) into cardiomyocytes without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.04-18-2013
20130212720BIOMARKERS ASSOCIATED WITH AUTOIMMUNE DISEASES OF THE LUNG - The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease.08-15-2013

Patent applications in class The nonhuman animal is a model for human disease

Patent applications in all subclasses The nonhuman animal is a model for human disease